{"product_id":"uchicago-medicine-22nd-annual-international-ultmann-chicago-lymphoma-symposium-2025","title":"UChicago Medicine 22nd Annual International Ultmann Chicago Lymphoma Symposium 2025","description":"\u003ch1 class=\"product_title entry-title\"\u003eUChicago Medicine 22nd Annual International Ultmann Chicago Lymphoma Symposium 2025\u003c\/h1\u003e\r\n\u003cstrong\u003e+ Include: 27 Videos (.mp4) + 27 Audios (.mp3) + 27 Subtitles (.vtt) + 26 PDFs, size: 9.29 GB\u003c\/strong\u003e\r\n\r\n\u003cstrong\u003e+ Target Audience: practicing oncologists, hematologists\u003c\/strong\u003e\r\n\r\n\u003cstrong\u003e+ Information:\u003c\/strong\u003e\r\n\u003ch2 data-path-to-node=\"0\"\u003e1. Overview\u003c\/h2\u003e\r\n\u003cp data-path-to-node=\"1\"\u003eThe UChicago Medicine 22nd Annual International Ultmann Chicago Lymphoma Symposium 2025 provides an in-depth review of the latest clinical advancements in lymphoma diagnosis and management. The course explores novel targeted therapies, cellular treatments like CAR T-cells and bispecifics, genomic testing, and multidisciplinary strategies for managing complex and relapsed lymphoma cases.\u003c\/p\u003e\r\n\u003cp data-path-to-node=\"1\"\u003e\u003cb data-path-to-node=\"1\" data-index-in-node=\"390\"\u003eCourse Date:\u003c\/b\u003e 04\/04\/2025\u003c\/p\u003e\r\n\r\n\u003cdiv\u003e\r\n\r\nThe 22nd International Ultmann Chicago Lymphoma Symposium (IUCLS) is a continuation of an annual conference dedicated solely to the science and clinical care of lymphoma. It has been organized to honor the achievements of Dr. John Ultmann, a pioneer in the treatment of lymphoma, who devoted his life to the understanding of this disease. He was particularly known for his work on the staging of Hodgkin lymphoma and the utility of staging as a guide for treatment.\r\n\r\nThe goal of this educational activity is to facilitate a forum for physicians, nurses, researchers, and other healthcare professionals to discuss biologic, diagnostic, and therapeutic aspects of Hodgkin and non-Hodgkin lymphoma.\r\n\r\nThis event gives opportunities for providers to explore vital information on clinical updates and research in order to ensure they are using the latest treatment options in their practice.\r\n\r\n\u003c\/div\u003e\r\n\u003ch2 data-path-to-node=\"2\"\u003e2. Learning Objectives\u003c\/h2\u003e\r\n\u003cul data-path-to-node=\"3\"\u003e\r\n \t\u003cli\u003eAt the conclusion of this educational activity, participants will be able to:\r\n\u003cul\u003e\r\n \t\u003cli\u003e\r\n\u003cdiv\u003eAssess clinical trial results of approved and investigational treatment strategies being studied in patients with indolent and aggressive subtypes of B-cell and T-cell non-Hodgkin lymphoma\u003c\/div\u003e\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cdiv\u003eCompare and contrast the selection and sequencing of therapeutic approaches for the care of patients with newly diagnosed and relapsed\/refractory Hodgkin lymphoma\u003c\/div\u003e\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cdiv\u003eEvaluate the various patient and disease-related factors that may impact therapeutic decisions for patients with newly diagnosed and previously treated CLL\/SLL\u003c\/div\u003e\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cdiv\u003eReview approaches to the care of patients with rarer hematologic malignancies, including CNS lymphoma and Waldenstrom macroglobulinemia\u003c\/div\u003e\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cdiv\u003eIdentify and nurture strategies to enhance communication and collaboration with the entire multidisciplinary healthcare team during the continuum of care of patients with lymphoma\u003c\/div\u003e\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch2 data-path-to-node=\"4\"\u003e3. Target Audience\u003c\/h2\u003e\r\nBest for hematologists and oncologists who want updates on cellular therapies, genomic testing, and clinical management of complex lymphomas.\r\n\r\nThe target audience for this symposium is practicing oncologists, hematologists, advanced nurse practitioners, physician assistants, residents, fellows, nurses, pharmacists, and the other health professionals interested in the treatment and diagnosis of lymphoma.\r\n\u003ch2 data-path-to-node=\"6\"\u003e4. Topics\u003c\/h2\u003e\r\n\u003cul data-path-to-node=\"8\"\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,0,0\"\u003e01 Nivo-AVD for Advanced Stage Hodgkin Lymphoma\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,1,0\"\u003e02 Bv-AVD for Advanced Stage Hodgkin Lymphoma\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,2,0\"\u003e03 Contributions of the European Regimens to the Management of cHL\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,3,0\"\u003e04 The Impact of 1L Therapy Selection on Subsequent HL Treatment Approaches\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,4,0\"\u003e05 Prioritizing Clinical Research in Oncology Clinical Practice\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,5,0\"\u003e06 Comparison of CAR T-Cell Therapies in RR Follicular Lymphoma\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,6,0\"\u003e07 Comparison of Bispecific Therapies in RR Follicular Lymphoma\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,7,0\"\u003e08 Non-T-Cell Engaging Treatment Options in RR Follicular Lymphoma\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,8,0\"\u003e09 How I Approach Treatment-Naive CLL SLL\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,9,0\"\u003e10 Challenges in Treating Patients with TP53-Mutated MCL\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,10,0\"\u003e11 Role of Transplant and Cellular Therapy in RR MCL\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,11,0\"\u003e12 Globalizing Lymphoma Research – Challenges and Opportunities\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,12,0\"\u003e13 Current Role of BTK Inhibitors in Frontline MCL\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,13,0\"\u003e14 Overview of Treatment Options and Key Trials for CNS Lymphoma\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,14,0\"\u003e15 A Ticking Time B-Cell Lymphoma – A Case on High-Risk DLBCL for CNS Relapse\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,15,0\"\u003e16 Challenging Case Discussion – Newly Diagnosed Low-Grade FL Transformed Into Double-hit DLBCL With Secondary CNS Lymph…\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,16,0\"\u003e17 Frontline Treatment Options in Newly Diagnosed DLBCL\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,17,0\"\u003e18 RR DLBCL – The Role of CAR T-Cells vs. Bispecifics in First Relapse\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,18,0\"\u003e19 FrailOlder Patients With DLBCL – A Persistent Challenge\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,19,0\"\u003e20 Baseline Genomic Testing in Lymphoma – Are We There Yet\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,20,0\"\u003e21 Next Generation Hematopathology and the Standard of Care in Lymphoma\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,21,0\"\u003e22 Mediastinal Gray Zone Lymphoma Case-Based Panel Discussion – Diagnostic Criteria \u0026amp; Management Approach\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,22,0\"\u003e23 Novel Therapies for Lymphoma – Focus on CELMoDs and BTK Degraders\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,23,0\"\u003e24 Novel T-Cell Engaging Therapy Approaches – How Close are They to Prime Time\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,24,0\"\u003e25 Improving HRQoL for Patients With Lymphoma\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,25,0\"\u003e26 Nursing Perspective on Managing Neurotoxicity – What Tools Do We Have\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,26,0\"\u003e27 Incorporating Patient-Reported Outcomes in Clinical Trials\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e","brand":"My Store","offers":[{"title":"Default Title","offer_id":42954563485794,"sku":"MED-AMB06154","price":20.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0662\/9549\/6802\/files\/UChicago-Medicine-22nd-Annual-International-Ultmann-Chicago-Lymphoma-Symposium-2025.jpg?v=1779379777","url":"https:\/\/meducourse.com\/products\/uchicago-medicine-22nd-annual-international-ultmann-chicago-lymphoma-symposium-2025","provider":"Meducourse","version":"1.0","type":"link"}